Adalimumab's Effectiveness in Reducing Autoantibodies in Rheumatoid Arthritis
Author Information
Author(s): Fabiola Atzeni, Piercarlo Sarzi-Puttini, Donata Dell'Acqua, Simona de Portu, Germana Cecchini, Carola Cruini, Mario Carrabba, Pier Luigi Meroni
Primary Institution: L Sacco University Hospital, Milan, Italy
Hypothesis
Does treatment with adalimumab reduce rheumatoid factor and anti-cyclic citrullinated peptide antibody levels in patients with rheumatoid arthritis?
Conclusion
Adalimumab treatment significantly reduces rheumatoid factor and anti-CCP antibody levels in rheumatoid arthritis patients, correlating with clinical improvement.
Supporting Evidence
- 88% of patients achieved an ACR 20 response at 24 weeks.
- Significant decrease in RF and anti-CCP levels was observed after 24 weeks.
- Induction of antinuclear autoantibodies was found in 28% of patients after 12 months.
Takeaway
This study shows that a medicine called adalimumab helps people with arthritis by lowering certain harmful proteins in their blood, which makes them feel better.
Methodology
A one-year prospective study involving 57 rheumatoid arthritis patients treated with adalimumab, measuring autoantibody levels at baseline, 6 months, and 12 months.
Potential Biases
Potential selection bias as patients were chosen based on their non-responsiveness to previous treatments.
Limitations
The study had a relatively small sample size and included only patients not responsive to methotrexate.
Participant Demographics
57 patients (53 women, 4 men) with a mean age of 56 years.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website